Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Indanazoline is a synthetic imidazoline derivative and small molecule drug primarily used as a topical nasal decongestant for the treatment of acute, chronic, and allergic rhinitis. It acts as an alpha-adrenergic receptor agonist on vascular smooth muscle cells in the nasal mucosa, inducing vasoconstriction that reduces mucosal edema and relieves nasal congestion. Systemically, it can cause increased blood pressure and reduced heart rate at doses much higher than those used therapeutically. Additional pharmacological effects observed in animal models include antiphlogistic (anti-inflammatory), spasmolytic (smooth muscle relaxant), hyperglycemic, and diuretic actions. Indanazoline is generally well tolerated locally with minimal risk of rebound congestion or mucosal damage at recommended intranasal doses[2][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Indanazoline.